Search

Search Constraints

You searched for: Author/Creator Pol, Stanislas

Search Results

92. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Issue 2 (1st February 2020)

93. Safety of sitagliptin in treatment of hepatocellular carcinoma in chronic liver disease patients. Issue 3 (28th August 2021)

94. Securing wider EU commitment to the elimination of hepatitis C virus. (14th December 2022)

95. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed. Issue 1 (20th May 2015)

96. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed. Issue 1 (20th May 2015)

97. Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. Issue 10 (13th November 2015)

98. Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort. Issue 10 (21st May 2020)

99. Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B. Issue 8 (August 2018)

100. The dynamic effect of direct‐acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. Issue 12 (22nd August 2019)